<DOC>
	<DOCNO>NCT00696644</DOCNO>
	<brief_summary>This observational study evaluate incidence new vertebral non vertebral fragility fracture patient severe osteoporosis treat anabolic drug . This study also evaluate BMD , compliance treatment , back pain health-related quality life .</brief_summary>
	<brief_title>A Study Teriparatide Severe Osteoporosis</brief_title>
	<detailed_description>The participant treat anabolic therapy osteoporosis ( Teriparatide PTH 1-84 ) 18 month follow subsequent 6 month . The treatment expect improve bone mineral density , back pain reduce risk new fracture due osteoporosis . The outcome evaluate bone densitometry lumbar spine femoral neck , standard radiograph , measurement bone formation marker ( P1NP ) questionnaires back pain quality life . Postmenopausal woman men 21 year old may include : 1. least 3 severe vertebral fracture 2 . 2 severe vertebral fracture 1 hip fracture 3. incidental vertebral fracture hip fracture treatment antiresorptives prescribe least 12 month .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman men older 21 year affect severe osteoporosis incidental vertebral hip fracture treatment antiresorptive , 3 severe vertebral fracture 2 severe vertebral fracture historical hip fracture . Any contraindication use antiosteoporotic drug Premenopausal woman men young 21 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>